Cambridge Investment Research Advisors, Inc. Acurx Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 15,000 shares of ACXP stock, worth $5,250. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,000
Previous 17,750
15.49%
Holding current value
$5,250
Previous $14,000
57.14%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ACXP
# of Institutions
27Shares Held
3.49MCall Options Held
100Put Options Held
0-
Sabby Management, LLC Upper Saddle River, NJ2.04MShares$715,5916.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA529KShares$185,2720.0% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$128,3010.08% of portfolio
-
Geode Capital Management, LLC Boston, MA171KShares$60,0200.0% of portfolio
-
Morgan Stanley New York, NY106KShares$37,1700.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $4.04M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...